Print

NeoGenomics, Inc. (NGNM.OB) Reports 181% Increase in Adjusted EBITDA on 38% Revenue Growth and Achieves Profitability in 2012  
2/14/2013 8:48:04 AM

FT. MYERS, Fla., Feb. 14, 2013 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year 2012.
Fiscal Year 2012 Highlights:
* 50% Test Volume Growth
* 38% Revenue Growth
* 181% Increase in Adjusted EBITDA
* Net Income of $65K, or $0.00 per Share

//-->